Safety study of LY03020 for healthy volunteers and people with schizophrenia
Part of Mental health clinical trials.
This study tests the safety of a new medication called LY03020. It is for healthy volunteers and for people with stable schizophrenia. The study aims to see how well the body handles the drug and what side effects might occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old (healthy volunteers) or 18 to 60 years old (if you have schizophrenia).
- You weigh at least 50 kg (men) or 45 kg (women) and have a BMI between 18.5 and 26 (healthy) or up to 32 (if you have schizophrenia).
- If you have schizophrenia, your symptoms must be stable and you must meet certain clinical scores.
- You cannot have significant medical conditions, eye problems, or a history of fainting when standing up.
- You cannot have used certain medications or supplements recently; for people with schizophrenia, some restrictions apply.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (LY03020) for people with schizophrenia who are currently having a flare-up of symptoms severe enough to require hospital care. The goal is to see if the drug safely reduces psychotic symptoms like hallucinations and delusions.
This trial tests if a new drug called VV119 is safe and how it works in the body. It is for healthy volunteers and for people who have had schizophrenia for at least a year and are currently having worsening symptoms.
This early-phase study looks at how a new investigational drug (LY03017) moves through the body when taken with or without food, and how it works in younger adults (18–45) compared to older adults (65+). Participation could help researchers find the right dose and understand how the drug is processed, which is a first step toward finding a treatment.
This trial tests a new medication called LB-102 for people with acute (sudden worsening of) schizophrenia. It aims to see if the drug helps reduce symptoms like hallucinations or disorganized thinking.
This study tests a new medicine, KR23248, in healthy people to see if it is safe and how the body handles it. It is a first-in-human trial, so the main goal is to find out about side effects and how the drug moves through the body.
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.